States increasingly struggling to cover the rising cost of popular GLP-1 drugs like Wegovy, Ozempic and Zepbound are searching for ways to get out from under the budgetary squeeze that took them

While gastrointestinal issues are the most common side effects, a recent study by the University of British Columbia linked GLP-1 (glucagon-like peptide-1) agonists — the class of drugs that includes semaglutides — to an increased risk of hair loss.

The number of Americans taking cutting-edge weight-loss drugs like Ozempic, Wegovy and Zepbound has skyrocketed in recent years, a new study says.